Sentences with phrase «lung cancer patients compared»

Not exact matches

Meanwhile, Bristol - Myers rolled out data from a new analysis comparing Opdivo and its fellow BMS immunotherapy Yervoy against Opdivo alone in previously untreated lung cancer patients.

PET scans showed dramatically increased glucose metabolism in the lungs of 20 immune - compromised pediatric cancer patients with flu and other respiratory infections compared to patients without infections.

Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

Ceritinib significantly improved patient - reported outcomes including lung cancer - specific symptoms and overall health status, compared to placebo (p < 0.05).

In this study, researchers compared the effectiveness of the immunotherapy drug nivolumab (pronounced «nye VOL ue mab,» marketed at Opdivo), with standard - of - care chemotherapy in 541 patients with previously untreated or recurrent non-small cell lung cancer (NSCLC) that expressed PDL - 1 antibodies.

Islam and colleagues found that among patients with localized lung cancer, those with one comorbidity had a 30 percent higher risk of mortality compared with those who had no comorbidity.

Perera began working with Weinstein on a small study comparing two groups of hospital patients: One group was suffering from lung cancer; the other was a group of orthopedic patients as a control sample.

A lung cancer diagnosis appears to put patients at the greatest risk of suicide when compared to the most common types of non-skin cancers, according to new research presented at the ATS 2017 International Conference.

The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to...

The purpose of this study is to compare the effectiveness of daratumumab in combination with atezolizumab against atezolizumab alone in patients who have advanced non-small cell lung cancer (NSCLC) that has previously been treated.

DENVER — Elderly patients with stage III non-small cell lung cancer (NSCLC) showed improved overall survival (OS) when treated with chemoradiation (CRT) compared to definitive radiation (RT) alone.

Lung cancer treatment is an evolving field of science, currently there are several pathways under investigation as a possible treatment target.1 - 3 Targeted treatment is currently considered to be more efficient compared to the non-specific cytotoxic drugs, however; the small number of patients identified with mutations, limit the application of these drugs.

Patients, especially those with larger tumors, who undergo thoracoscopic resections might have improved cancer specific survival compared with those undergoing SABR for early stage non-small lung cancer

Life table modelling on the basis of these data estimated 33 % five year survival in 65 year old patients with early stage non-small cell lung cancer who continued to smoke compared with 70 % in those who quit smoking.

The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer survival compared to those who took docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).